{"id":"W2313602753","doi":"10.1158/0008-5472.sabcs11-p4-11-14","title":"P4-11-14: Number Needed To Treat (NNT) as a Measure of Incremental Drug Benefit: Denosumab vs. Zoledronic Acid for the Prevention of Skeletal Related Events (SREs) in Advanced Breast Cancer.","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Novartis (Canada); Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Denosumab; Medicine; Number needed to treat; Zoledronic acid; Breast cancer; Randomized controlled trial; Oncology; Urology; Internal medicine; Surgery; Relative risk; Cancer; Osteoporosis; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0499659,0.001352802,0.005898938,0.001933667,0.0003392753,0.001726951,0.001778746,0.002689661,0.01072834],"category_scores_gemma":[0.07041023,0.0005177618,0.009298888,0.001695222,0.001722305,0.002208647,0.001523945,0.005383672,0.0008011074],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002666801,"about_ca_system_score_gemma":0.001598918,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008784006,"about_ca_topic_score_gemma":0.0009486236,"domain_scores_codex":[0.9214577,0.06710202,0.002659782,0.002360031,0.005927226,0.0004932181],"domain_scores_gemma":[0.9301257,0.0632957,0.003457378,0.001085014,0.001207209,0.0008290466],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.4165567,0.001433727,0.03780801,0.0209424,0.09000187,0.0005977484,0.000353087,0.03842776,0.00179084,0.01603174,0.03218228,0.3438738],"study_design_scores_gemma":[0.1583234,0.1134591,0.1185349,0.008036032,0.1078302,0.003339448,0.0007062054,0.285052,0.008049858,0.09348334,0.1022911,0.0008945604],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"other","genre_scores_codex":[0.4988547,0.2582329,0.1092369,0.02311707,0.01723206,0.0209617,0.02304364,0.001086788,0.0482342],"genre_scores_gemma":[0.9337521,0.005514324,0.03723661,0.003756969,0.001084415,0.008986924,0.003119798,0.0002028921,0.006346095],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.0499659,"threshold_uncertainty_score":0.2642481,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05851396126191138,"score_gpt":0.4121546398440055,"score_spread":0.3536406785820941,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}